Rosemont Pharmaceuticals is seeking to expand its US specialty medicines business through a proposed acquisition of Aytu BioPharma, a US-based company focused on treatments for complex central nervous system (CNS) conditions.
The companies have entered into a definitive merger agreement under which a wholly owned subsidiary of Rosemont will launch a tender offer for all outstanding Aytu common shares at $2.70 per share in cash.
The offer represents a 41.1 per cent premium to Aytu's 30-day volume-weighted average share price. The transaction has been unanimously approved by Aytu's board of directors, with completion anticipated in late December 2026, subject to the satisfaction or waiver of the relevant conditions.
The proposed acquisition forms part of Rosemont's strategy to expand its international specialty pharmaceutical business and strengthen its position in the US market.
Aytu has an established portfolio focused on adult and paediatric CNS treatments, alongside commercial capabilities that Rosemont expects to combine with its own product development, regulatory, manufacturing and commercial expertise.
Alok Sonig, chief executive of Rosemont Pharmaceuticals, said the deal represented an important step in the company's US growth strategy.
He said Aytu had built a differentiated portfolio and established commercial capabilities, adding that the combination could create a platform for further growth.
How will the acquisition be structured?
The transaction will take place through a tender offer followed by a second-stage merger.
Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days. Aytu will file a Schedule 14D-9 with the US Securities and Exchange Commission at substantially the same time, setting out its position on the offer and further details of the process.
The tender offer is subject to customary conditions, including the tender of shares representing at least a majority of Aytu's outstanding common stock and the exercise or termination of certain outstanding warrants.
Following successful completion of the offer, Rosemont will acquire the remaining shares through a second-step merger at the same $2.70-per-share price, apart from shares for which appraisal rights are properly exercised.
Aytu's executive officers, directors and certain shareholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements. Under these arrangements, they have agreed to tender their shares and address certain warrants in accordance with the transaction terms.
Until completion, both businesses will continue to operate independently. Rosemont and Aytu have said that maintaining continuity of supply and service for customers and partners will be a priority during the transition.
Josh Disbrow, chief executive of Aytu BioPharma, said the agreement reflected the company's work in developing its CNS and paediatric portfolio.
He said Rosemont's experience in developing and commercialising specialty medicines offered a strategic fit with Aytu's business and that the proposed transaction provided value to shareholders.
What does the deal mean for Rosemont's US expansion?
The acquisition would strengthen Rosemont's position in the US specialty pharmaceutical market, adding Aytu's CNS-focused portfolio and commercial expertise to its existing operations.
The companies also expect to draw on complementary capabilities, including Rosemont's product development, regulatory and manufacturing experience and Aytu's commercial infrastructure, which includes omnichannel and digital marketing.
Rosemont is backed by Inflexion, a European-headquartered mid-market private equity firm with offices in London, New York, Amsterdam, Frankfurt and Stockholm. Inflexion reports $21 billion in assets under management and established a dedicated team in New York in 2025.
The acquisition would add to Rosemont's international growth ambitions, although the announcement does not disclose specific financial projections, expected cost savings or changes to the companies' product portfolios following completion.
Bourne Partners is acting as financial adviser to Rosemont, with Ropes & Gray LLP serving as its legal counsel. Canaccord Genuity is advising Aytu, while Dorsey & Whitney LLP is its legal counsel.
The proposed deal remains subject to the tender offer conditions and other customary closing requirements. Both companies will continue operating separately until the transaction is completed.












